A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Roche’s Imvigor-130 study supports Tecentriq’s continued use in urothelial bladder cancer – up to a point.
Away from the main small-molecule focus of this year’s Esmo meeting, Keytruda flies the flag for immuno-oncology, including in a little-noticed mesothelioma study.
Issues with manufacturing, not exactly a new problem for Immunomedics, derail the company’s bid for glory.
Shutdown or no, drug reviews are still under way, giving the sector something to look forward to as 2019 kicks off.
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.